2. Endocrinology

Endocrinology

Endocrinology

Related Products

PDF 21.44 MB

Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system’s function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS).

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162480
    PTP1B-IN-27 98%
    PTP1B-IN-27 (Compound 7i) is an inhibitor of protein tyrosine phosphatase 1-B (PTP‐1B)(IC50=8.2 µM). PTP1B-IN-27 also inhibits α-Glucosidase (IC50=120 µM) and shows competitive inhibition (Ki=118 µM).
    PTP1B-IN-27
  • HY-162547
    Oxogestone phenpropionate 16915-80-3 98%
    Oxogestone phenpropionate is a progesterone that can be used in studies to regulate hormone levels.
    Oxogestone phenpropionate
  • HY-163373
    13,14-Dihydro-15-keto prostaglandin D1 1392219-79-2 98%
    13,14-Dihydro-15-keto prostaglandin D1 is a derivative of prostaglandin D1.
    13,14-Dihydro-15-keto prostaglandin D1
  • HY-163485
    AR antagonist 8 98%
    AR antagonist 8 (compound 16), an unnatural entestrane, is a potent Lupeol-inspired androgen receptor (AR) antagonist with an IC50 of 0.76 μM.
    AR antagonist 8
  • HY-164034
    Ganglefene 299-61-6 98%
    Ganglefene is a blocker for n-choline receptor, which leads to the sexual dysfunction in the offspring in adulthood, when administrated to pregnant rats.
    Ganglefene
  • HY-16474S
    Relugolix-d6 98%
    Relugolix-d6 is deuterium labeled Relugolix. Relugolix (TAK-385)?is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.
    Relugolix-d6
  • HY-16508S
    Ulipristal acetate-d6 1621894-64-1 98%
    Ulipristal acetate-d6 is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma.
    Ulipristal acetate-d6
  • HY-165478
    FCE 28260 155651-56-2
    FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH).
    FCE 28260
  • HY-165489
    AU-006 220831-12-9
    AU-006 is an orally active inhibitor of gastric acid secretion, with anti-ulcer effects. AU-006 does not rely on NO and mucus regulation. AU-006 significantly prevents 95% of gastric mucosal damage caused by ethanol and has broad-spectrum protective effects against chemical corrosive damage. AU-006 can be used for research on gastric ulcers.
    .
    AU-006
  • HY-165595
    Glutamic acid-alanine-glycine mixture 8058-79-5 98%
    The glutamic acid-alanine-glycine mixture is an orally active activator of testosterone 5α-reductase (5α-reductase). It promotes prostate function by enhancing the activity of 5α-reductase and increasing the levels of free amino acids. However, when combined with testosterone and estradiol (HY-B0141R), the glutamic acid-alanine-glycine mixture inhibits 5α-reductase activity and decreases the levels of free amino acids. The glutamic acid-alanine-glycine mixture can be used in research related to prostate function and endocrine disorders.
    Glutamic acid-alanine-glycine mixture
  • HY-16622B
    GSK 1842799 hydrochloride 1277165-15-7 98%
    GSK 1842799 hydrochloride is a selective S1P1 receptor agonist with potent agonist activity and exceptional selectivity over S1P3. GSK 1842799 hydrochloride demonstrates good oral bioavailability and rapid conversion to its active phosphorylated form. GSK 1842799 hydrochloride significantly reduces blood lymphocyte counts in vivo following oral administration. GSK 1842799 hydrochloride has shown efficacy comparable to FTY720 in the mouse EAE model of multiple sclerosis.
    GSK 1842799 hydrochloride
  • HY-167878
    Pentomone 67102-87-8 98%
    Pentomone (LY-113935), an antiandrogen compound, is a prostate growth inhibitor.
    Pentomone
  • HY-167925
    Rec 15/2615 173059-47-7 98%
    Rec 15/2615 is a potent α(1)-adrenergic agonist that stimulates small cholangiocyte proliferation through the activation of calcium-dependent signaling pathways.
    Rec 15/2615
  • HY-167932
    Mifepristone methochloride 109345-60-0 98%
    Mifepristone (RU486) methochloride is a glucocorticoid antagonist that blocks peripheral glucocorticoid and progesterone receptors. Mifepristone methochloride has been shown to have minimal effects on intraocular pressure in treated rabbits. Mifepristone methochloride was developed as a water-soluble formulation to enhance ocular penetration of the drug.
    Mifepristone methochloride
  • HY-168397
    tetranor-Prostaglandin E1 23923-84-4 98%
    tetranor-Prostaglandin E1 is metabolite of Prostaglandin E1 (HY-B0131) and Prostaglandin E2 (HY-101952) that is formed by β-oxidation.
    tetranor-Prostaglandin E1
  • HY-168436
    Tyrosinase-IN-40 98%
    Tyrosinase-IN-40 (Compound 9r) is a competitive-type tyrosinase inhibitor, with an IC50 value of 17.02  µM, a Ki value of 14.87 µM. Tyrosinase-IN-40 displays antioxidant activity. Tyrosinase-IN-40 can be used in melanin-related studies.
    Tyrosinase-IN-40
  • HY-169223
    Roxatidine hydrochloride 97900-88-4 98%
    Roxatidine hydrochloride is an anti-ulcer compound with the activity of inhibiting gastric acid secretion. Roxatidine hydrochloride effectively inhibits duodenal and gastric ulcers and reduces ulcer pain. Roxatidine hydrochloride has a better safety profile than other similar compounds due to the lower dose required for effective inhibition.
    Roxatidine hydrochloride
  • HY-169777
    WAY-214156 1007853-40-8 98%
    WAY-214156 is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of ERβ.
    WAY-214156
  • HY-170056
    2α-Methyl-5α-androstan-17-one-3α-glucuronide 361432-78-2 98%
    2α-Methyl-5α-androstan-17-one-3α-glucuronide is a metabolite of Drostanolone.
    2α-Methyl-5α-androstan-17-one-3α-glucuronide
  • HY-17005R
    Olmesartan medoxomil (Standard) 144689-63-4 99.68%
    Olmesartan medoxomil (Standard) is the analytical standard of Olmesartan medoxomil. This product is intended for research and analytical applications. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil (Standard)
Cat. No. Product Name / Synonyms Application Reactivity